Close
FINDING CURES TOGETHER<sup>SM</sup>

Program

Daily Schedule - Monday - September 22

Continental Breakfast 
7:00 a.m.-8:00 a.m.
 

Plenary Session 3: Genomics
Session Chairperson: Riccardo Dalla-Favera, Columbia University Institute for Cancer Genetics, New York, N.Y.
8:00 a.m.-10:00 a.m.

Acute lymphoblastic leukemia: Recent insights from genomic profiling into pathophysiology and therapy
Charles G. Mullighan, St. Jude Children’s Research Hospital, Memphis, TN

The evolutionary landscape of chronic lymphocytic leukemia
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Mass.

Pathogenetic and therapeutic insights from the genome of diffuse large B cell lymphoma
Riccardo Dalla-Favera

AML genomics: An update
Elaine R. Mardis, Washington University School of Medicine, St. Louis, Mo.
 

Break
10:00 a.m.-10:30 a.m.
 

Concurrent Sessions 1-2
10:30 a.m.-12:30 p.m.

Concurrent Session 1: Leukemia
Session Chairperson: Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Mass.

An oncogenic enhancer drives NOTCH1-induced leukemia
Adolfo Ferrando, Columbia University, New York, N.Y.

Integrating chemical and functional genomics for leukemia discovery
Kimberly Stegmaier

Regulation of acute leukemia initiation and progression by long noncoding RNAs
Iannis Aifantis, New York University Langone Medical Center, New York, N.Y.

The histone demethylase Jmjd1c is required for MLL-AF9 leukemia initiating cell homeostasis through modulating Hoxa9-controlled transcription program
Nan Zhu, Memorial Sloan Kettering Cancer Center, New York, N.Y.*

Investigating the use of tyrosine kinase inhibitors in Ph-like ALL
Kathryn G. Roberts, St. Jude Children’s Research Hospital, Memphis, Tenn.*

Delineating the roles of lysine 27 methylation-associated epigenetic modulators in T cell leukemia
Panagiotis Ntziachristos, NYU Langone Medical Center, New York, N.Y.*
 

Concurrent Session 2: Myeloma
Session Chairperson: Jonathan D. Licht, Northwestern University, Chicago, Ill.
 
Targeting genetic heterogeneity in multiple myeloma through immune activation
P. Lief Bergsagel, Mayo Clinic, Scottsdale, Ariz.

Aberrant histone methylation in multiple myeloma
Jonathan D. Licht, Northwestern University, Chicago, Ill.

Genomic-based treatment advances in Waldenstrom’s macroglobulinemia
Steven P. Treon, Dana-Farber Cancer Institute, Boston, Mass.

New insights into therapeutic targets in multiple myeloma
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Mass.

Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma

Francesca Cottini, Dana-Farber Cancer Institute, Boston, Mass.*
 

Lunch
12:30 p.m.-1:00 p.m.

 

Panel Discussion 2: Implementation of Clinical Genomics
1:00 p.m.-2:30 p.m.
Session Chairperson: Randy D. Gascoyne, BC Cancer Agency, Vancouver, B.C., Canada

Panelists

Comprehensive clinical genomic profiling in hematolymphoid malignancies: An overview
Vincent A. Miller, Foundation Medicine, Inc., Cambridge, Mass.

Implementation of clinical genomics: Promise and challenges
John D. Carpten, TGen, Phoenix, Ariz.

How might next-generation sequencing penetrate clinical practice for lymphoid malignancies?
Randy D. Gascoyne


Discussion


Plenary Session 4: Cell Death Pathways
Session Chairperson: Suzanne Cory, The Walter and Eliza Hall Institute Of Medical Research, Melbourne, Australia
2:30 p.m.-4:30 p.m.

Using mitochondria to guide leukemia therapy
Anthony G. Letai, Dana-Farber Cancer Institute, Boston, Mass.

How cells survive: Single cell analysis reveals properties of nongenetic apoptosis resistance
Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, Tenn.

Harnessing death for life
Suzanne Cory

BCL-2 inhibition – An example of translational medicine – Update
Gary B. Gordon, AbbVie Inc., North Chicago, Ill.


Break
4:30 p.m.-5:00 p.m.
 

Panel Discussion 3: Clinical Research: Now and in the Future
Session Chairperson: James H. Doroshow, National Cancer Institute, Bethesda, Md.
5:00 p.m.-6:30 p.m.

Panelists
Peter F. Lebowitz, Janssen Research & Development, Spring House, Pa.

James H. Doroshow

Ann Farrell, U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, Md.


Dinner on Own

6:30 p.m.-8:00 p.m.


Poster Session B and Reception
8:00 p.m.-10:30 p.m.

*Short talks from proffered abstracts